University of California

University of Pennsylvania

Shangpharma Innovation Inc.

Shanghai Chempartner Co., Ltd

Hyunil Jo

William F Degrado

Dean Sheppard

Aparna Sundaram

Joel McIntosh

Richard Thomas Beresis

Youzhi Tang

Nilgun Isik Reed

Marc Adler

Jun Wang

Jizhou Wang

Belgin Canturk

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

Inhibitors of alpha 2 beta 1 integrin and methods of use thereof

Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.

Inhibitors of integrin alpha 2 beta 1 and methods of use

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

Alpha-5 beta-1 inhibitors

Disclosed herein, inter alia, are inhibitors of integrin alpha 5 beta 1 and methods of using the same.

Inhibitors of integrin alpha 5 beta 1 and methods of use

Provided herein, inter alia, are methods and compositions for inhibiting &#x3b1;v&#x3b2;1 integrin and for treating fibrosis.

Anti-alphavbeta1 integrin inhibitors and methods of use

Anti-alphavbeta1 integrin compounds and methods

Provided are compounds according to formula (Ia) or (Ib) as described herein, that are capable of modulating the activity of influenza viruses (e.g., influenza A virus), for example, via interaction with the M2 transmembrane protein, and other similar viroporins. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds according to according to formulas (Ia') or (Ib), as described herein.

Growing community of inventors

Lafayette, CA, United States of America

Hyunil Jo